{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:24:14Z","timestamp":1754162654619,"version":"3.41.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"DOI":"10.7759\/cureus.89054","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:06:27Z","timestamp":1753880787000},"source":"Crossref","is-referenced-by-count":0,"title":["Novel Therapies in Advanced Pancreatic Cancer: A Peak Beyond the Realms of Gene Targeting"],"prefix":"10.7759","author":[{"given":"Prashil","family":"Dave","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Beriwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charmy","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiren","family":"Dayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj H","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Punith Chowdary","family":"Chirumamilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Winer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein AP","year":"2021","unstructured":"Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021, 18:493-502. 10.1038\/s41575-021-00457-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi JD","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, et al.. Pancreatic cancer. Lancet. 2020, 395:2008-20. 10.1016\/S0140-6736(20)30974-0","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.884349","article-title":"Two novel nomograms predicting the risk and prognosis of pancreatic cancer patients with lung metastases: a population-based study","volume":"10","author":"Zhang W","year":"2022","unstructured":"Zhang W, Ji L, Zhong X, et al.. Two novel nomograms predicting the risk and prognosis of pancreatic cancer patients with lung metastases: a population-based study. Front Public Health. 2022, 10:884349. 10.3389\/fpubh.2022.884349","journal-title":"Front Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092067","article-title":"Can surgical resection of metastatic lesions be beneficial to pancreatic ductal adenocarcinoma patients with isolated lung metastasis?","volume":"14","author":"Yun WG","year":"2022","unstructured":"Yun WG, Kwon W, Han Y, et al.. Can surgical resection of metastatic lesions be beneficial to pancreatic ductal adenocarcinoma patients with isolated lung metastasis?. Cancers (Basel). 2022, 14:10.3390\/cancers14092067","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23943","article-title":"The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas","volume":"112","author":"Downs-Canner S","year":"2015","unstructured":"Downs-Canner S, Zenati M, Boone BA, et al.. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas. J Surg Oncol. 2015, 112:80-5. 10.1002\/jso.23943","journal-title":"J Surg Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: the critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters AM","year":"2018","unstructured":"Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018, 8:10.1101\/cshperspect.a031435","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00659-4","article-title":"The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives","volume":"6","author":"Wang S","year":"2021","unstructured":"Wang S, Zheng Y, Yang F, et al.. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021, 6:249. 10.1038\/s41392-021-00659-4","journal-title":"Signal Transduct Target Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao W","year":"2022","unstructured":"Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, Yu J. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022, 10:38. 10.1186\/s40364-022-00385-1","journal-title":"Biomark Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-020-00490-5","article-title":"KRAS mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer","volume":"101","author":"Singh K","year":"2021","unstructured":"Singh K, Pruski M, Bland R, et al.. KRAS mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Lab Invest. 2021, 101:177-92. 10.1038\/s41374-020-00490-5","journal-title":"Lab Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail L","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020, 17:153-68. 10.1038\/s41575-019-0245-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian Y","year":"2020","unstructured":"Qian Y, Gong Y, Fan Z, et al.. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020, 13:130. 10.1186\/s13045-020-00958-3","journal-title":"J Hematol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001324","article-title":"Next-generation sequencing in pancreatic cancer","volume":"48","author":"Shen GQ","year":"2019","unstructured":"Shen GQ, Aleassa EM, Walsh RM, Morris-Stiff G. Next-generation sequencing in pancreatic cancer. Pancreas. 2019, 48:739-48. 10.1097\/MPA.0000000000001324","journal-title":"Pancreas"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","author":"Holter S","year":"2015","unstructured":"Holter S, Borgida A, Dodd A, et al.. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015, 33:3124-9. 10.1200\/JCO.2014.59.7401","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2017.07.007","article-title":"Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas","volume":"17","author":"Tanaka M","year":"2017","unstructured":"Tanaka M, Fern\u00e1ndez-Del Castillo C, Kamisawa T, et al.. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017, 17:738-53. 10.1016\/j.pan.2017.07.007","journal-title":"Pancreatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3861","article-title":"Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma","volume":"49","author":"Feigin ME","year":"2017","unstructured":"Feigin ME, Garvin T, Bailey P, et al.. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet. 2017, 49:825-33. 10.1038\/ng.3861","journal-title":"Nat Genet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris HA 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, et al.. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997, 15:2403-13. 10.1200\/JCO.1997.15.6.2403","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.019","article-title":"Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials","volume":"49","author":"Ciliberto D","year":"2013","unstructured":"Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer. 2013, 49:593-603. 10.1016\/j.ejca.2012.08.019","journal-title":"Eur J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0394","article-title":"Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer","volume":"20","author":"Tabernero J","year":"2015","unstructured":"Tabernero J, Chiorean EG, Infante JR, et al.. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015, 20:143-50. 10.1634\/theoncologist.2014-0394","journal-title":"Oncologist"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy T","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al.. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011, 364:1817-25. 10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0185","article-title":"An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions","volume":"16","author":"Lowery MA","year":"2011","unstructured":"Lowery MA, Kelsen DP, Stadler ZK, et al.. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011, 16:1397-402. 10.1634\/theoncologist.2011-0185","journal-title":"Oncologist"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham D","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD, et al.. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009, 27:5513-8. 10.1200\/JCO.2009.24.2446","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"34","author":"Gill S","year":"2016","unstructured":"Gill S, Ko YJ, Cripps C, et al.. PANCREOX: a randomized phase III study of fluorouracil\/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016, 34:3914-20. 10.1200\/JCO.2016.68.5776","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny B","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T, et al.. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020, 26:878-85. 10.1038\/s41591-020-0880-x","journal-title":"Nat Med"},{"key":"ref25","unstructured":"GB1275 monotherapy and in combination with an anti-PD1 antibody in patients with specified advanced solid tumors or in combination with standard of care in patients with metastatic pancreatic adenocarcinoma. (2022). https.\/\/clinicaltrials.gov\/study\/NCT04060342."},{"key":"ref26","unstructured":"Safety and efficacy of APX005m with gemcitabine and nab-paclitaxel with or without nivolumab in patients with previously untreated metastatic pancreatic adenocarcinoma. (2022). https.\/\/clinicaltrials.gov\/study\/NCT03214250."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara MH","year":"2021","unstructured":"O\u2019Hara MH, O\u2019Reilly EM, Varadhachary G, et al.. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021, 22:118-31. 10.1016\/S1470-2045(20)30532-5","journal-title":"Lancet Oncol"},{"key":"ref28","unstructured":"Epacadostat, pembrolizumab, and CRS-207, with or without CY\/\u200bGVAX pancreas in patients with metastatic pancreas cancer. (2024). https.\/\/clinicaltrials.gov\/study\/NCT03006302."},{"key":"ref29","unstructured":"A multi-cancer, multi-state, platform study of durvalumab (MEDI4736) and oleclumab (MEDI9447) in pancreatic adenocarcinoma, non-small cell lung cancer and squamous cell carcinoma of the head and neck to correlate clinical, molecular and immunologic parameters with DNA methylation (DOME). (2020). https.\/\/clinicaltrials.gov\/study\/NCT04262388."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.665","article-title":"ARC-8: phase 1\/1b randomized study of quemliclustat + gemcitabine\/nab-paclitaxel \u00b1 zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma","volume":"42","author":"Wainberg ZA","year":"2024","unstructured":"Wainberg ZA, Gulam Abbas Manji, Bahary N, et al.. ARC-8: phase 1\/1b randomized study of quemliclustat + gemcitabine\/nab-paclitaxel \u00b1 zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma. J Clin Oncol. 2024, 42:10.1200\/JCO.2024.42.3_suppl.665","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4018","article-title":"Masitinib plus gemcitabine as first-line treatment of pancreatic cancer with pain: results from phase 3 study AB12005","volume":"39","author":"Ezenfis J","year":"2021","unstructured":"Ezenfis J, Hermine O. Masitinib plus gemcitabine as first-line treatment of pancreatic cancer with pain: results from phase 3 study AB12005. J Clin Oncol. 2021, 39:15. 10.1200\/JCO.2021.39.15_suppl.4018","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4023","article-title":"Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500)","volume":"40","author":"Agop P","year":"2022","unstructured":"Agop P, Bahary N, Amit Mahipal, et al.. Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500). J Clin Oncol. 2022, 40:16. 10.1200\/JCO.2022.40.16_suppl.4023","journal-title":"J Clin Oncol"},{"key":"ref33","unstructured":"Study of AG-270 in participants with advanced solid tumors or lymphoma with MTAP loss. (2024). https.\/\/clinicaltrials.gov\/study\/NCT03435250."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.581","article-title":"A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma","volume":"40","author":"Yin C","year":"2023","unstructured":"Yin C, Marshall J, Laura Ann Macke, et al.. A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2023, 40:4. 10.1200\/JCO.2022.40.4_suppl.581","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4666","article-title":"Trybeca-1: a randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441)","author":"Hammel P","year":"2022","unstructured":"Hammel P, Iman El-Hariry, Macarulla T, et al.. Trybeca-1: a randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441). J Clin Oncol. 2022, 10.1200\/JCO.2020.38.15_suppl.TPS4666","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.330","article-title":"A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer","volume":"37","author":"Pelzer U","year":"2019","unstructured":"Pelzer U, Bendell JC, Womack MS, et al.. A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer. J Clin Oncol. 2019, 37:330. 10.1200\/JCO.2019.37.4_suppl.330","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1773201","article-title":"Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients","volume":"9","author":"Lum LG","year":"2020","unstructured":"Lum LG, Thakur A, Choi M, et al.. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Oncoimmunology. 2020, 9:1773201. 10.1080\/2162402X.2020.1773201","journal-title":"Oncoimmunology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS782","article-title":"Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): phase 2, open-label, randomized study","volume":"41","author":"Park W","year":"2022","unstructured":"Park W, Eileen Mary O'Reilly, Junji Furuse, et al.. Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): phase 2, open-label, randomized study. J Clin Oncol. 2022, 41:10.1200\/JCO.2023.41.4_suppl.TPS782","journal-title":"J Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas AR","year":"2019","unstructured":"Haas AR, Tanyi JL, O'Hara MH, et al.. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019, 27:1919-29. 10.1016\/j.ymthe.2019.07.015","journal-title":"Mol Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4140","article-title":"Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy","volume":"41","author":"Park W","year":"2023","unstructured":"Park W, O\u2019Connor C, Chou JF, et al.. Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy. J Clin Oncol. 2023, 41:16. 10.1200\/JCO.2023.41.16_suppl.4140","journal-title":"J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT514","article-title":"A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5\/6 inhibitor, BI 905677, in patients with advanced solid tumors","author":"\u00c9lez E","year":"2022","unstructured":"\u00c9lez E, Lenz HJ, Maja de Jonge, et al.. A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5\/6 inhibitor, BI 905677, in patients with advanced solid tumors. Cancer Res. 2022, 10.1158\/1538-7445.AM2022-CT514","journal-title":"Cancer Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong DS","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, et al.. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020, 383:1207-17. 10.1056\/NEJMoa1917239","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, et al.. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020, 21:271-82. 10.1016\/S1470-2045(19)30691-6","journal-title":"Lancet Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3654","article-title":"A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors","volume":"38","author":"Schram AM","year":"2020","unstructured":"Schram AM, Drilon AE, Macarulla T, et al.. A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors. J Clin Oncol. 2020, 38:15. 10.1200\/JCO.2020.38.15_suppl.TPS3654","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/375577-novel-therapies-in-advanced-pancreatic-cancer-a-peak-beyond-the-realms-of-gene-targeting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:06:30Z","timestamp":1753880790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/375577-novel-therapies-in-advanced-pancreatic-cancer-a-peak-beyond-the-realms-of-gene-targeting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.89054","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}